Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis

Company Overview

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration. In parallel, Lineage is advancing oligodendrocyte progenitor cell therapies for spinal cord injury and conducting early-stage programs in immune-effector cell oncology, including dendritic cell-based vaccines and natural killer-cell products intended to stimulate or enhance anti-tumor responses.

Founded in the 1990s as BioTime and rebranded in late 2019, Lineage Cell Therapeutics is headquartered in Carlsbad, California, with research and development activities extending into clinical sites across the United States and Europe. The company’s leadership team is led by President and Chief Executive Officer Brian Culley, supported by an experienced scientific advisory board. Through its integrated development strategy, Lineage aims to translate stem cell science into scalable therapies that address significant unmet medical needs in ophthalmology, neurology and oncology.

Key Stats

• Today's Range: $1.46 to $1.58
• 50-Day Range: $0.94 to $1.55
• 52-Week Range: $0.37 to $1.62
• Volume: 1.86 million shs
• Average Volume: 1.40 million shs
• Market Capitalization: $349.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.25
• Consensus Rating: Buy

Lineage Cell Therapeutics Stock Analysis - MarketRank™

Lineage Cell Therapeutics scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Lineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Lineage Cell Therapeutics has a consensus price target of $4.25, representing about 177.8% upside from its current price of $1.53.

Amount of Analyst Coverage

Lineage Cell Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.12) to ($0.09) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lineage Cell Therapeutics is -8.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lineage Cell Therapeutics is -8.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lineage Cell Therapeutics has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.18% of the float of Lineage Cell Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Lineage Cell Therapeutics has recently increased by 1.08%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lineage Cell Therapeutics does not currently pay a dividend.

Dividend Growth

Lineage Cell Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.18% of the float of Lineage Cell Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Lineage Cell Therapeutics has recently increased by 1.08%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

42 people have searched for LCTX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

3 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.80% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LCTX Stock Analysis - Frequently Asked Questions

How have LCTX shares performed this year?

Lineage Cell Therapeutics' stock was trading at $0.5150 at the beginning of 2025. Since then, LCTX shares have increased by 197.1% and is now trading at $1.53.

How were Lineage Cell Therapeutics' earnings last quarter?

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.03) earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. The company earned $1.41 million during the quarter, compared to analyst estimates of $1.28 million. Lineage Cell Therapeutics had a negative trailing twelve-month return on equity of 20.00% and a negative net margin of 374.84%.
Read the conference call transcript.

Who are Lineage Cell Therapeutics' major shareholders?

Lineage Cell Therapeutics' top institutional investors include Defender Capital LLC. (2.97%), Raffles Associates LP (2.36%), Geode Capital Management LLC (1.06%) and Y Intercept Hong Kong Ltd (0.18%). Insiders that own company stock include Broadwood Partners, LP, Brian M Culley, Don M Bailey and Jill Ann Howe.
View institutional ownership trends.

How do I buy shares of Lineage Cell Therapeutics?

Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lineage Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lineage Cell Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Moderna (MRNA), JPMorgan Chase & Co. (JPM) and Chevron (CVX).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 9/21/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:LCTX
• CIK: 876343
• Web: www.lineagecell.com
• Phone: (442) 287-8963
• Fax: 510-521-3389
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lineage Cell Therapeutics: $4.25
• High Price Target: $9.00
• Low Price Target: $2.00
• Potential Upside/Downside: +177.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.61 million
• Net Margins: -374.84%
• Pretax Margin: -373.45%
• Return on Equity: -20.00%
• Return on Assets: -12.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.08
• Quick Ratio: 4.08

Sales & Book Value

• Annual Sales: $9.50 million
• Price / Sales: 36.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 4.37

Miscellaneous

• Outstanding Shares: 228,360,000
• Free Float: 167,157,000
• Market Cap: $349.39 million
• Optionable: Not Optionable
• Beta: 1.66